Stock Analysis:Allergan Inc (NYSE:AGN) Stock Target Upgraded
In an interesting research report revealed to clients by Leerink Swann on Wednesday, 2 December, Allergan Inc (NYSE:AGN) had its target price per share boosted to $393.00. The firm currently has a solid Outperform rating on shares.
From a total of 15 analysts covering Allergan Inc. (NYSE:AGN) stock, 18 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $400 while the lowest target price is $308. The mean of all analyst targets is $364.87 with a 12.73% above today’s ($321.21) stock price. Allergan Inc. was the topic of 20 analyst reports since July 29, 2015 according to the firm StockzIntelligence Inc. Mizuho maintained shares on November 24 with “Buy” rating. Vetr upgraded shares to “Buy” rating and $354.98 target share price in a report from an August 24. Leerink Swann maintained AGN stock in a recent report from October 28 with “Outperform” rating. Canaccord Genuity maintained the rating on August 9. Canaccord Genuity has a “Buy” rating and a $396 price target on shares. Finally, Nomura initiated the stock with “Buy” rating in a report issued on a September 29.
Approximately 767,093 shares of stock traded hands. Allergan PLC (NYSE:AGN) has risen 11.89% since April 29, 2015 and is uptrending. It has outperformed by 12.09% the S&P500.
According to Zacks Investment Research, “Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.” Get a free copy of the Zacks research report on Allergan PLC (AGN).